Novel Radionuclide Treatment Demonstrates Promising Results in mCRPC

Excerpt:

“Updated results from the phase II LuPSMA study published in The Lancet Oncology showed radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival (PFS) in men with progressive metastatic castrate-resistant prostate cancer (mCRPC) compared with previous results with another radiopharmaceutical, radium-223 (Ra-223; Xofigo).

“In LuPSMA, the median PSA PFS was 7.6 months (95% CI, 6.3-9.0) and 27 (90%) of 30 men experienced PSA progression. The median overall survival (OS) was 13.5 months (95% CI, 10.4-22.7) and 22 (73%) men had died by the November 2017 data cutoff.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer

Excerpt:

“NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy. The Phase 1 study has completed its second round of patient enrollment, with the first six patients having undergone dosing. The researchers will be discussing the trial on June 5 at the 2017 American Society of Clinical Oncology meeting in Chicago.

“The researchers are using the small molecule Lutetium 177Lu-PSMA-617 to target prostate-specific membrane antigen (PSMA), a protein that is abundantly expressed in 85-90 percent of metastasized prostate cancers. The small molecule binds to PSMA and delivers precise radiation therapy intended to shrink the cancer — even in cases in which cells have yet to form a visible tumor on a bone or CT scan.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.